|
Pronunciation |
|
(hye
DRAL a zeen, hye droe klor oh
THYE a zide, & re SER peen) |

|
|
U.S. Brand
Names |
|
Hydrap-ES®; Marpres®;
Ser-Ap-Es® |

|
|
Generic
Available |
|
Yes |

|
|
Synonyms |
|
Hydrochlorothiazide, Hydralazine, and Reserpine; Reserpine, Hydralazine, and
Hydrochlorothiazide |

|
|
Pharmacological Index |
|
Antihypertensive Agent, Combination |

|
|
Use |
|
Hypertensive disorders |

|
|
Pregnancy Risk
Factor |
|
C |

|
|
Usual Dosage |
|
Adults: Oral: 1-2 tablets 3 times/day |

|
|
Dietary
Considerations |
|
May be administered with meals |

|
|
Cardiovascular
Considerations |
|
Combination therapy for the treatment of hypertension should be
individualized for each patient. Potential advantages for this combination
therapy may include improved compliance and synergistic reductions in blood
pressure with an accompanied reduction in side effects. Thiazide therapy
improves cardiovascular outcomes in patients with hypertension. Reserpine is
infrequently used as monotherapy for hypertension due to side
effects. |

|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |

|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |

|
|
Patient
Information |
|
See individual agents. Pregnancy precautions: Inform prescriber if
you are or intend to get pregnant. |

|
|
Dosage Forms |
|
Tablet: Hydralazine 25 mg, hydrochlorothiazide 15 mg, and reserpine 0.1
mg |

|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|